Coronary flow reserve and coronary microvascular functions are strongly related to serum uric acid concentrations in healthy adults

Coronary Artery Disease

Volumn 17, Issue 1, 2006, Pages 7-14

  Erdogan, Dogan ^a   Gullu, Hakan ^a   Caliskan, Mustafa ^a   Yildirim, Ibrahim ^a   Ulus, Taner ^a   Bilgi, Muhammet ^a   Yilmaz, Sema ^a   Muderrisoglu, Haldun ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Coronary artery disease; Coronary flow reserve; Doppler echocardiography; Uric acid

Indexed keywords

DIPYRIDAMOLE; URIC ACID; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD FLOW VELOCITY; BLOOD FLOWMETRY; BLOOD VESSEL FUNCTION; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORRELATION ANALYSIS; DIASTOLE; ECHOCARDIOGRAPHY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MICROVASCULATURE; NORMAL HUMAN; PRIORITY JOURNAL; URIC ACID BLOOD LEVEL; ADOLESCENT; BLOOD; COMPARATIVE STUDY; CORONARY BLOOD VESSEL; DOPPLER ECHOCARDIOGRAPHY; ECHOGRAPHY; HEART CONTRACTION; MICROCIRCULATION; MIDDLE AGED; OXIDATIVE STRESS; PHYSIOLOGY; REFERENCE VALUE;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BLOOD FLOW VELOCITY; CORONARY CIRCULATION; CORONARY VESSELS; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; MALE; MICROCIRCULATION; MIDDLE AGED; MYOCARDIAL CONTRACTION; OXIDATIVE STRESS; REFERENCE VALUES; URIC ACID;

EID: 33646978364     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200602000-00002     Document Type: Article

References (39)

1. Waring WS, Webb DJ, Maxwell SR. Syetemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharmacol 2001; 38:65-71.
2. Waring WS, Convery A, Mishra V, Shenkin A, Webb DJ, Maxwell SR. Uric acid reduces exercise-induced oxidative stress in healthy adults. Clin Sci (Lond) 2003; 105:425-430.
3. Regoli F, Winston GW. Quantification of total oxidant scavenging capacity of antioxidants for peroxynitrite, peroxyl radicals, and hydroxyl radicals. Toxicol Appl Pharmacol 1999; 156:96-105.
4. Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I epidemiologic follow-up study. Am J Epidemiol 1995; 141:637-644.
5. Alderman MH. Uric acid and cardiovascular risk. Curr Opin Pharmacol 2002; 2:126-130.
6. Caiati C, Zedda N, Montaldo C, Montischi R, Iliceto S. Contrast-enhanced transthoracic second harmonic echo Doppler with adenosine: a noninvasive, rapid and effective method for coronary flow reserve assessment. J Am Coll Cardiol 1999; 34:122-130.
7. Lambertz H, Tries HP, Stein T, Lethen H. Noninvasive assessment of coronary flow reserve with transthoracic signal-enhanced Doppler echocardiography. J Am Soc Echocardiogr 1999; 12:186-195.
8. Saraste M, Koskenvuo J, Knuuti J, Toikka J, Laine H, Niemi P, et al. Coronary flow reserve: measurement with transthoracic Doppler echocardiography is reproducible and comparable with positron emission tomography. Clin Physiol 2001; 21:114-122.
9. Ruilope LM, Garcia-Puig J. Hyperuricemia and renal function. Curr Hypertens Rep 2001; 3:197-202.
10. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55:613-618.
11. Mylonas C, Kouretas D. Lipid peroxidation and tissue damage. In Vivo 1999; 13:295-309.
12. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340:115-126.
13. Habdous M, Herbeth B, Vincent-Viry M, Lamont JV, Fitzgerald PS, Visvikis S, et al. Serum total antioxidant status, erythrocyte superoxide dismutase and whole-blood glutathione peroxidase activities in the Stanislas cohort: Influencing factors and reference intervals. Clin Chem Lab Med 2003; 41:209-215.
14. Nojiri S, Daida H, Mokuno H, Iwama Y, Mae K, Ushio F, et al. Association of serum antioxidant capacity with coronary artery disease in middle-aged men. Jpn Heart J 2001; 42:677-690.
15. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Intern Med 1999; 31:7-13.
16. Niskanen LK, Laaksonen DE, Nyyssonen K, Alfthan G, Lakka HM, Lakka TA, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in the middle-aged men: a prospective cohort study. Arch Intern Med 2004; 164:1546-1551.
17. Iribarren C, Folsom AR, Eckfeldt JH, McGovern PG, Nieto FJ. Correlates of uric acid and its association with asymptomatic carotid atherosclerosis: The ARIC Study. Ann Epidemiol 1996; 6:331-340.
18. Freedman DS, Wiliamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease. Am J Epidemiol 1995; 141:637-644.
19. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41:1183-1190.
20. Tykarski A. Evaluation of renal handling of uric acid in essential hypertension: hyperuricemia related to decreased urate secretion. Nephron 1991; 59:364-368.
21. Leyva F, Anker S, Swan JW, Godsland IF, Wingrove CS, Chua TP, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997; 18:858-865.
22. Cappuccio FP, Strazzullo P, Farinaro E, Trevisan M. Uric acid metabolism and tubular sodium handling. Results from a population-based study. J Am Med Assoc 1993; 270:354-359.
23. Conen D, Wietlisbach V, Bovet P, Shamlaye C, Riesen W, Paccaud F, et al. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health 2004; 4:9.
24. Bonora E, Targher G, Zenere MB, Saggiani F, Cacciatori V, Tosi F, et al. Relationship of uric acid concentration to cardiovascular risk factors in young men. The role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study. Int J Obes Relat Metab Disord 1996; 20:975-980.
25. Zavaroni I, Mazza S, Fantuzzi M, Dall'Aglio E, Bonora E, Delsignore R, et al. Changes in insulin and lipid metabolism in males with asymptomatic hyperuricemia. J Intern Med 1993; 234:25-30.
26. Rathmann W, Funkhouser E, Dyer AR, Roseman JM. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: The CARDIA Study - Coronary Artery Risk Development in Young Adults. Annals Epidemiol 1998; 8:250-261.
27. Lee J, Sparrow D, Vokonas PS, Landsberg L, Weiss ST. Uric acid and coronary heart disease risk: evidence for a role of uric acid in the obesity-insulin resistance syndrome. The Normative Aging Study. Am J Epidemiol 1995; 142:288-294.
28. Agamah ES, Srinivasan SR, Webber LS, Berenson GS. Serum uric acid and its relations to cardiovascular disease risk factors in children and young adults from a biracial community: The Bogalusa Heart Study. J Lab Clin Med 1991; 118:241-249.
29. Maxwell AJ, Tsao PS, Cooke JP. Modulation of the nitric oxide synthase pathway in atherosclerosis. Exp Physiol 1998; 83:573-584.
30. Houston M, Chumley P, Radi R, Rubbo H, Freeman BA. Xanthine oxidase reaction with nitric oxide and peroxynitrite. Arch Biochem Biophys 1998; 355:1-8.
31. Lee CI, Liu X, Zweier JL. Regulation of xanthine oxidase by nitric oxide and peroxynitrite. J Biol Chem 2000; 275:9369-9376.
32. Kaufmann PA, Gnecchi-Ruscone T, di Terlizzi M, Schafers KP, Luscher TF, Camici PG. Coronary heart disease in smokers: vitamin C restores coronary microcirculatory function. Circulation 2000; 102:1233-1238.
33. Coppola A, Astarita C, Liguori E, Fontana D, Oliviero M, Esposito K, et al. Impairment of coronary circulation by acute hyperhomocysteinaemia and reversal by antioxidant vitamins. J Intern Med 2004; 256:398-405.
34. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. J Am Med Assoc 2000; 283:2404-2410.
35. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, et al. Effects of xanthine oxidase inhibition with allopuinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002; 105:2619-2624.
36. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109:2818-2825.
37. Tamakoshi K, Yatsuya H, Kondo T, Hori Y, Ishikawa M, Zhang H, et al. The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low grade inflammatory stage. Int J Obes Relat Metab Disord 2003; 27:443-449.
38. Hozumi T, Yoshida K, Akasaka T, Asami Y, Ogata Y, Takagi T, et al. Noninvasive assessment of coronary flow velocity and coronary flow velocity reserve in the left anterior descending coronary artery by Doppler echocardiography: comparison with invasive technique. J Am Coll Cardiol 1998; 32:1251-1259.
39. Hozumi T, Yoshida K, Ogata Y, Akasaka T, Asami Y, Takagi T, Morioka S. Noninvasive assessment of significant left anterior descending coronary artery stenosis by coronary flow velocity reserve with transthoracic color Doppler echocardiography. Circulation 1998; 97:1557-1562.